Novel immunological targets in rheumatic diseases: clues from current therapies
• We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology.
Gespeichert in:
| Autor*in: |
D’Acquisto, Fulvio [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Triazolopyridazine LRRK2 kinase inhibitors - 2013, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:19 ; year:2014 ; number:8 ; pages:1155-1160 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.drudis.2014.06.021 |
|---|
| Katalog-ID: |
ELV022989137 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV022989137 | ||
| 003 | DE-627 | ||
| 005 | 20230623165306.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2014.06.021 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014019000010.pica |
| 035 | |a (DE-627)ELV022989137 | ||
| 035 | |a (ELSEVIER)S1359-6446(14)00256-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 630 |q VZ |
| 084 | |a 22 |2 ssgn | ||
| 084 | |a 46.00 |2 bkl | ||
| 100 | 1 | |a D’Acquisto, Fulvio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel immunological targets in rheumatic diseases: clues from current therapies |
| 264 | 1 | |c 2014 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. | ||
| 700 | 1 | |a Rattazzi, Lorenza |4 oth | |
| 700 | 1 | |a Piras, Giuseppa |4 oth | |
| 700 | 1 | |a Galuppo, Maria Letteria |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Triazolopyridazine LRRK2 kinase inhibitors |d 2013 |g Amsterdam [u.a.] |w (DE-627)ELV011759550 |
| 773 | 1 | 8 | |g volume:19 |g year:2014 |g number:8 |g pages:1155-1160 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.drudis.2014.06.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 46.00 |j Tiermedizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 19 |j 2014 |e 8 |h 1155-1160 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
f d fd |
|---|---|
| matchkey_str |
dacquistofulviorattazzilorenzapirasgiuse:2014----:oeimnlgclagtiremtciesslef |
| hierarchy_sort_str |
2014 |
| bklnumber |
46.00 |
| publishDate |
2014 |
| allfields |
10.1016/j.drudis.2014.06.021 doi GBVA2014019000010.pica (DE-627)ELV022989137 (ELSEVIER)S1359-6446(14)00256-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl D’Acquisto, Fulvio verfasserin aut Novel immunological targets in rheumatic diseases: clues from current therapies 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. Rattazzi, Lorenza oth Piras, Giuseppa oth Galuppo, Maria Letteria oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:19 year:2014 number:8 pages:1155-1160 extent:6 https://doi.org/10.1016/j.drudis.2014.06.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 19 2014 8 1155-1160 6 045F 610 |
| spelling |
10.1016/j.drudis.2014.06.021 doi GBVA2014019000010.pica (DE-627)ELV022989137 (ELSEVIER)S1359-6446(14)00256-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl D’Acquisto, Fulvio verfasserin aut Novel immunological targets in rheumatic diseases: clues from current therapies 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. Rattazzi, Lorenza oth Piras, Giuseppa oth Galuppo, Maria Letteria oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:19 year:2014 number:8 pages:1155-1160 extent:6 https://doi.org/10.1016/j.drudis.2014.06.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 19 2014 8 1155-1160 6 045F 610 |
| allfields_unstemmed |
10.1016/j.drudis.2014.06.021 doi GBVA2014019000010.pica (DE-627)ELV022989137 (ELSEVIER)S1359-6446(14)00256-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl D’Acquisto, Fulvio verfasserin aut Novel immunological targets in rheumatic diseases: clues from current therapies 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. Rattazzi, Lorenza oth Piras, Giuseppa oth Galuppo, Maria Letteria oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:19 year:2014 number:8 pages:1155-1160 extent:6 https://doi.org/10.1016/j.drudis.2014.06.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 19 2014 8 1155-1160 6 045F 610 |
| allfieldsGer |
10.1016/j.drudis.2014.06.021 doi GBVA2014019000010.pica (DE-627)ELV022989137 (ELSEVIER)S1359-6446(14)00256-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl D’Acquisto, Fulvio verfasserin aut Novel immunological targets in rheumatic diseases: clues from current therapies 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. Rattazzi, Lorenza oth Piras, Giuseppa oth Galuppo, Maria Letteria oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:19 year:2014 number:8 pages:1155-1160 extent:6 https://doi.org/10.1016/j.drudis.2014.06.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 19 2014 8 1155-1160 6 045F 610 |
| allfieldsSound |
10.1016/j.drudis.2014.06.021 doi GBVA2014019000010.pica (DE-627)ELV022989137 (ELSEVIER)S1359-6446(14)00256-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl D’Acquisto, Fulvio verfasserin aut Novel immunological targets in rheumatic diseases: clues from current therapies 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. Rattazzi, Lorenza oth Piras, Giuseppa oth Galuppo, Maria Letteria oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:19 year:2014 number:8 pages:1155-1160 extent:6 https://doi.org/10.1016/j.drudis.2014.06.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 19 2014 8 1155-1160 6 045F 610 |
| language |
English |
| source |
Enthalten in Triazolopyridazine LRRK2 kinase inhibitors Amsterdam [u.a.] volume:19 year:2014 number:8 pages:1155-1160 extent:6 |
| sourceStr |
Enthalten in Triazolopyridazine LRRK2 kinase inhibitors Amsterdam [u.a.] volume:19 year:2014 number:8 pages:1155-1160 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Tiermedizin: Allgemeines |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| authorswithroles_txt_mv |
D’Acquisto, Fulvio @@aut@@ Rattazzi, Lorenza @@oth@@ Piras, Giuseppa @@oth@@ Galuppo, Maria Letteria @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011759550 |
| dewey-sort |
3610 |
| id |
ELV022989137 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022989137</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623165306.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drudis.2014.06.021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014019000010.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022989137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-6446(14)00256-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">D’Acquisto, Fulvio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel immunological targets in rheumatic diseases: clues from current therapies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rattazzi, Lorenza</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Piras, Giuseppa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galuppo, Maria Letteria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Triazolopyridazine LRRK2 kinase inhibitors</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011759550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:1155-1160</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drudis.2014.06.021</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2014</subfield><subfield code="e">8</subfield><subfield code="h">1155-1160</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
D’Acquisto, Fulvio |
| spellingShingle |
D’Acquisto, Fulvio ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 Novel immunological targets in rheumatic diseases: clues from current therapies |
| authorStr |
D’Acquisto, Fulvio |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011759550 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences 630 - Agriculture & related technologies |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Novel immunological targets in rheumatic diseases: clues from current therapies |
| topic |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| topic_unstemmed |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| topic_browse |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l r lr g p gp m l g ml mlg |
| hierarchy_parent_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| hierarchy_parent_id |
ELV011759550 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry 630 - Agriculture |
| hierarchy_top_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011759550 |
| title |
Novel immunological targets in rheumatic diseases: clues from current therapies |
| ctrlnum |
(DE-627)ELV022989137 (ELSEVIER)S1359-6446(14)00256-6 |
| title_full |
Novel immunological targets in rheumatic diseases: clues from current therapies |
| author_sort |
D’Acquisto, Fulvio |
| journal |
Triazolopyridazine LRRK2 kinase inhibitors |
| journalStr |
Triazolopyridazine LRRK2 kinase inhibitors |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
1155 |
| author_browse |
D’Acquisto, Fulvio |
| container_volume |
19 |
| physical |
6 |
| class |
610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
D’Acquisto, Fulvio |
| doi_str_mv |
10.1016/j.drudis.2014.06.021 |
| dewey-full |
610 540 630 |
| title_sort |
novel immunological targets in rheumatic diseases: clues from current therapies |
| title_auth |
Novel immunological targets in rheumatic diseases: clues from current therapies |
| abstract |
• We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. |
| abstractGer |
• We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. |
| abstract_unstemmed |
• We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
8 |
| title_short |
Novel immunological targets in rheumatic diseases: clues from current therapies |
| url |
https://doi.org/10.1016/j.drudis.2014.06.021 |
| remote_bool |
true |
| author2 |
Rattazzi, Lorenza Piras, Giuseppa Galuppo, Maria Letteria |
| author2Str |
Rattazzi, Lorenza Piras, Giuseppa Galuppo, Maria Letteria |
| ppnlink |
ELV011759550 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.drudis.2014.06.021 |
| up_date |
2024-07-06T17:40:37.759Z |
| _version_ |
1803852330052878336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022989137</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623165306.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drudis.2014.06.021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014019000010.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022989137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-6446(14)00256-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">D’Acquisto, Fulvio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel immunological targets in rheumatic diseases: clues from current therapies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• We highlight areas of investigation to explore for the development of new classes of antirheumatic drugs. • Focus on immunological mechanisms that are currently targeted by clinically used therapeutics. • This review forms part of a section on rheumatology.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rattazzi, Lorenza</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Piras, Giuseppa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galuppo, Maria Letteria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Triazolopyridazine LRRK2 kinase inhibitors</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011759550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:1155-1160</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drudis.2014.06.021</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2014</subfield><subfield code="e">8</subfield><subfield code="h">1155-1160</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3994904 |